State Street
NMRA icon

State Street’s Neumora Therapeutics NMRA Stock Holding History

State Street’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
1,582,119
+1,183,400
+297% +$2.25M ﹤0.01% 3237
2026
Q1 		$778K Buy
398,719
+9,800
+3% +$25.4K ﹤0.01% 3547
2025
Q4 		$696K Hold
388,919
– – ﹤0.01% 3603
2025
Q3 		$708K Buy
388,919
+37,674
+11% +$60.9K ﹤0.01% 3589
2025
Q2 		$258K Sell
351,245
-1,370,559
-80% -$1.04M ﹤0.01% 3764
2025
Q1 		$1.72M Sell
1,721,804
-337,661
-16% -$578K ﹤0.01% 3298
2024
Q4 		$21.8M Buy
2,059,465
+268,758
+15% +$3.22M ﹤0.01% 2183
2024
Q3 		$23.7M Buy
1,790,707
+707,409
+65% +$8.25M ﹤0.01% 2109
2024
Q2 		$10.6M Buy
1,083,298
+824,114
+318% +$8.53M ﹤0.01% 2527
2024
Q1 		$3.56M Buy
259,184
+117,706
+83% +$1.9M ﹤0.01% 3062
2023
Q4 		$2.41M Buy
+141,478
New +$1.74M ﹤0.01% 3253

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street's NMRA Position: Q2 2026 in Review

State Street increased its Neumora Therapeutics (NMRA) stake by 297% in Q2 2026, buying an estimated $2.25M and bringing the position to 1,582,119 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3237.

State Street first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $23.7M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • State Street held 1,582,119 shares of Neumora Therapeutics worth $2.69M as of Q2 2026.
  • State Street bought 1,183,400 Neumora Therapeutics shares in Q2 2026, an estimated $2.25M.
  • Neumora Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3237 holding.
  • State Street first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • State Street's Neumora Therapeutics position peaked at $23.7M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.